NTI Begins Autism Clinical Trials for Unique Cannabis Strain
Neurotech International Ltd (ASX: NTI) has begun its first clinical trials on children aged between 5 and 17 years with Autism Spectrum Disorder (ASD) for its unique cannabis strain.
Jonathan Jackson 16/12/2020
NTI Days Away from Crucial Lab Results – Can its Cannabis Strain Treat Autism?
Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.